Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06340984
PHASE3

Serum Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast

Sponsor: South Valley University

View on ClinicalTrials.gov

Summary

The aim of this study is to: 1. Evaluation of serum soluble intercellular adhesion molecule-1 (sICAM-1) level in acne vulgaris and compare it to control group 2. Evaluate its role in acne pathogenesis and its correlation with acne vulgaris severity 3. Evaluate the effect of Montelukast on serum (sICAM-1) level in acne vulgaris

Official title: Role of Intercellular Adhesion Molecule -1 in Acne Vulgaris Patients : Effect of Montelukast Therapy

Key Details

Gender

All

Age Range

15 Years - 35 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2024-06

Completion Date

2025-02

Last Updated

2024-04-03

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Montelukast 10 Mg Oral Tablet

group modrate and severe acne will receive Montelukast therapy , dose: 10mg/day, duration of therapy: three months., Quantitively assay of level of serum intercellular adhesion molecule -1 will be measured by performing an enzyme-linked immune sorbent assay (E LISA) in group moderate acne vs group severe acne pre Montelukast treatment and after three months of treatment vs control group